stockrowIonis Pharmaceuticals, Inc.
IONS Healthcare Biotechnology
Ionis Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $943.7 million, up 33.8% from fiscal 2024.
- Revenue
- −40.7%
- EPS
- −188.5%
- Free cash flow
- +299.3%
- Total debt
- +116.0%
Quarter to June 2026, against a year earlier
Follow IONS
Alert me
Ionis Pharmaceuticals, Inc. (IONS) Total debt
Ionis Pharmaceuticals, Inc.'s total debt at the end of fiscal 2025 was $1.8B, up 42.9% from $1.2B in fiscal 2024. At the end of the quarter to 30 June 2026 it was $1.4B. Over the past ten years it has ranged from $516.7M (fiscal 2016) to $1.8B (fiscal 2025) — the current reading is the highest in ten years. Ionis Pharmaceuticals, Inc. ranks 10th of 569 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $1.8B | 42.87% |
| FY2024 | $1.2B | (2.23%) |
| FY2023 | $1.3B | 6.98% |
| FY2022 | $1.2B | (3.36%) |
| FY2021 | $1.2B | 31.12% |
| FY2020 | $939.6M | 19.32% |
| FY2019 | $787.5M | 21.77% |
| FY2018 | $646.7M | 6.46% |
| FY2017 | $607.5M | 17.56% |
| FY2016 | $516.7M | (3.00%) |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $1.4B | 0.13% |
| Mar 2026 | $1.3B | (24.17%) |
| Dec 2025 | $1.8B | 198.60% |
| Sep 2025 | $595.9M | (4.73%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| IONS Ionis Pharmaceuticals, Inc. | $1.4B |
| MIRM Mirum Pharmaceuticals, Inc. compare | $731.3M |
| LGND Ligand Pharmaceuticals Incorporated compare | $679.9M |
| KOD Kodiak Sciences Inc. compare | $174.5M |
| AXSM Axsome Therapeutics, Inc. compare | $127.3M |
| CGON CG Oncology, Inc. compare | $3.0M |
| IMVT Immunovant, Inc. compare | $614.0K |
| ORKA Oruka Therapeutics, Inc. compare | $301.0K |
| BLTE Belite Bio, Inc. Sponsored ADR compare | — |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on IONS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement